CClinicalTrials.gg
RecruitingNCT03583684PRT-IUpdated Nov 10, 2025

Neuroimaging Predictors of Improvement to Pivotal Response Treatment (PRT) in Young Children With Autism

An interventional study of Pivotal Response Treatment Program (PRT-P) in Autism Spectrum Disorder and Autism, sponsored by Stanford University. Recruiting at 1 site in United States. Open to participants aged 2 Years to 4 Years. Per ClinicalTrials.gov, last updated 2025-11-10.

Sponsored by Stanford University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2018; still recruiting 7 years 10 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
2 Years to 4 Years
Sex
All
01

Study summary

Autism spectrum disorder (ASD) is a very heterogeneous disorder with limited empirically validated behavioral and biological interventions. The goal of this pilot investigation is to apply a biologically-based approach to identify predictors of treatment response in children with ASD who are receiving Pivotal Response Treatment (PRT), an evidence-based behavioral intervention. Specifically, the investigators propose to identify neuroimaging biomarkers of treatment response to a PRT program (PRT-P) targeting language deficits in young children with ASD who will be randomized to either PRT-P or to a delayed treatment group (DTG).

02

Conditions studied

  • Autism Spectrum Disorder
  • Autism

Keywords

  • Pivotal Response Treatment
  • Imaging
03

In context

Autism Spectrum Disorder

1,727 studies on the registry are indexed under Autism Spectrum Disorder; 504 are open to participants now.

This study's planned enrollment of 36 is below the median of 52 across 1,371 interventional studies indexed under Autism Spectrum Disorder.

Browse Autism Spectrum Disorder studies →

Lead sponsor

Stanford University is the lead sponsor of 2,117 studies on the registry; 425 are open to participants now.

Of its 259 completed or terminated interventional studies of FDA-regulated products, 197 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 4 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosis of Autism Spectrum Spectrum Disorder (ASD) based on clinical interview and Diagnostic and Statistical Manual, 5th edition (DSM-5) and confirmed using the Autism Diagnostic Interview Revised (ADI-R) and the Autism Diagnostic Observation Schedule (ADOS) and/or Brief Observation of Symptoms of Autism (BOSA) and/or Childhood Autism Rating Scale- Second Edition (CARS-2).
  • Outpatients between 2.0 and 4.11 years of age of either gender,
  • Children of all cognitive levels will be included as long as they are able to participate in the testing procedures to the extent that valid standard scores can be obtained
  • Language delay as measured by the Preschool Language Scale, 5th Edition (PLS-5) [at least 1 standard deviation behind for children age 2 and 3 years; and 2 standard deviations behind for children age 4],
  • Stable psychotropic medication(s) or biomedical intervention(s) for at least 1 month prior to baseline measurements with no anticipated changes during study participation,
  • Stable treatment [Applied Behavior Analysis (ABA), Floortime, or other interventions], speech therapy, and school placement for at least 1 month prior to baseline measurements with no expected changes during study participation,
  • No more than 60 minutes of 1:1 speech therapy per week,
  • The child's exposure to the English language must be sufficient that administration of standardized tests in English is appropriate for measuring progress,
  • The availability of at least one parent who can consistently participate in the training sessions and related activities, and
  • Successful completion of baseline brain scan.

Exclusion criteria

Exclusion Criteria:

  • Current or life-time diagnosis of severe psychiatric disorder (e.g., bipolar disorder),
  • Genetic abnormality (e.g., Fragile X)
  • Presence of active medical problem (e.g., unstable seizure disorder),
  • Receiving more than 15 hours of in home 1:1 Applied Behavior Analysis (ABA) per week
  • Magnetic Resonance (MR) contraindication (e.g., the presence of ferrous metal), or
  • Previous adequate Pivotal Response Treatment (PRT) trial.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Pivotal Response Treatment Program (PRT-P)

    The Pivotal Response Treatment Program (PRT-P) will consist of 3 parent-only sessions (60-90 min) and 13 family sessions with the parent and child (60-90 min). These 16 sessions are once per week over a 16 week period.

    Behavioral: Pivotal Response Treatment Program (PRT-P)

  • No intervention
    Delayed Treatment Group (DTG)

    Child continues stable treatments as usual in the community.

Interventions

  • BehavioralPivotal Response Treatment Program (PRT-P)

    The Pivotal Response Treatment Program (PRT-P) will consist of 3 parent-only sessions (60-90 min) and 13 family sessions with the parent and child (60-90 min). These 16 sessions are once per week over a 16 week period.

    Also known as: Pivotal Response Treatment

06

What researchers measure

Primary outcomes

  1. Change in Number of Child Utterances During a Structured Lab Observation (SLO)

    Time frame: Baseline, 16 Weeks

Secondary outcomes

  1. Change on MacArthur-Bates Communication Development Inventory (CDI)

    Time frame: Baseline, 16 Weeks

Other outcomes

  1. Change on Preschool Language Scale, 5th Edition (PLS-5)

    Time frame: Baseline, 16 Weeks

  2. Change on Mullen Scales of Early Learning

    Time frame: Baseline, 16 Weeks

  3. Change on Vineland Adaptive Behaviors Scales, 3rd Edition

    Time frame: Baseline, 16 Weeks

  4. Change on Clinical Global Impressions Scale (CGI)

    Time frame: Baseline, 16 Weeks

  5. Change on the Brief Observation of Social Communication Change (BOSCC) direct child observation assessment

    Time frame: Baseline, 16 Weeks

  6. Change on Parent Stress Index (PSI)

    Time frame: Baseline, 16 Weeks

  7. Change on Family Empowerment Scale (FES)

    Time frame: Baseline, 16 Weeks

  8. Change on General Self Efficacy Scale (GSES)

    Time frame: Baseline, 16 Weeks

07

Study locations

1 of 1 sites recruiting
  • Stanford University
    Stanford, California 94305-5719, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — We will submit de-identified clinical data to the NIMH Data Archive (NDA) data repository.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03583684
Lead sponsor
Stanford University
Collaborators
National Institute on Deafness and Other Communication Disorders (NIDCD)
Responsible party
Antonio Hardan (Principal Investigator, Stanford University) — Principal investigator
First posted
Jul 11, 2018
Start date
Dec 7, 2018
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Nov 10, 2025

Study contacts

Estefania Millan, MA
Contact
mmillan2@stanford.edu
(650) 736-1235
John Hegarty, PhD
Contact
hegartyj@stanford.edu
(650) 736-1235
Antonio Hardan, MD
principal investigator · Stanford University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion